Abstract Library

#153 Antibody formation against somatostatin analogues with altered biodistribution and dosimetry: a case with implications for PRRT

Introduction: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) has emerged as a powerful palliative therapy. I.v. administration of radiolabeled (e.g. Yttrium-90) somatostatin analogues (SA) results in high-dose local irradiation of all tumor sites. The radiolabelled SA accumulates in the tumors through receptor-mediated internalization depending on the expression of somatostatin receptors and the pharmacokinetics of the radiolabelled SA.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: VAN BINNEBEEK S

Authors: Van Binnebeek S, DeRoose C, Van Billoen B, Baete K, Mortelmans L,

Keywords: antibody, somatostatin analogue, 90Y-DOTATOC, dosimetry, PRRT, 68Ga-DOTATOC,